ASH 2018 | Current challenges for multiple myeloma therapy: 2, 3, 4-drug combinations
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
Joshua Richter, MD, of Mount Sinai Medical Center, New York, NY, highlights how despite the emergence of new and very exiting data that support the use of 2, 3 and 4-drug combinations for multiple myeloma (MM), the key challenge is that that we still do not know what the right therapy is for the right person, and more so for the high-risk populations. This interview was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Get great new content delivered to your inboxSign up